Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-12-10 00:00:00 ET · period of report 2024-12-06 · accession 0001883850-24-000050 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-10 | 2024-12-06 | REGN | Fenimore Christopher R. | CFO, SVP Fin | A - Grant | $0.00 | +2,591 | 17.9K | +17% | $0 |
| D | 2024-12-10 | 2024-12-09 | REGN | Fenimore Christopher R. | CFO, SVP Fin | F - Tax | $787.00 | -1,140 | 16.8K | -6% | -$897.2K |
| D | 2024-12-10 | 2024-12-06 | REGN | Fenimore Christopher R. | CFO, SVP Fin | A - Grant | $0.00 | +9,979 | 9,979 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-06 | A | A | 2,591 | $0.00 | 17,896 | D | — | — | |
| 2 | Common | Common Stock | 2024-12-09 | F | D | 1,140 | $787.00 | 16,756 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-12-06 | A | A | 9,979 | $0.00 | 9,979 | D | $771.64 · — to 2034-12-06 | 9,979 Common Stock | (F3) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |